[go: up one dir, main page]

MX2009004890A - Direccionamiento de subunidades alpha-1 o alpha-3 de na+, k+-atpasa en el tratamiento de enfermedades proliferativas. - Google Patents

Direccionamiento de subunidades alpha-1 o alpha-3 de na+, k+-atpasa en el tratamiento de enfermedades proliferativas.

Info

Publication number
MX2009004890A
MX2009004890A MX2009004890A MX2009004890A MX2009004890A MX 2009004890 A MX2009004890 A MX 2009004890A MX 2009004890 A MX2009004890 A MX 2009004890A MX 2009004890 A MX2009004890 A MX 2009004890A MX 2009004890 A MX2009004890 A MX 2009004890A
Authority
MX
Mexico
Prior art keywords
alpha
subunit
atpase
treatment
proliferative diseases
Prior art date
Application number
MX2009004890A
Other languages
English (en)
Inventor
Francis Darro
Robert Kiss
Eric Van Quaquebeke
Laurent Van Den Hove
Tatjana Mijatovic
Nancy Deneve
Original Assignee
Unibioscreen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unibioscreen Sa filed Critical Unibioscreen Sa
Publication of MX2009004890A publication Critical patent/MX2009004890A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03009—Na+/K+-exchanging ATPase (3.6.3.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención proporciona métodos, reactivos, formulaciones farmacéuticas y kits para el tratamiento de enfermedades proliferativas tales como tumores y cánceres. La invención describe dirigir subunidades seleccionadas de la Na+, K+.ATPasa, y especialmente la subunidad alfa-1 y/o la subunidad alfa-3 de la misma.
MX2009004890A 2006-11-09 2006-11-09 Direccionamiento de subunidades alpha-1 o alpha-3 de na+, k+-atpasa en el tratamiento de enfermedades proliferativas. MX2009004890A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2006/010739 WO2008055530A1 (en) 2006-11-09 2006-11-09 Targeting of alpha-1 or alpha-3 subunit of na+, k+-atpase in the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
MX2009004890A true MX2009004890A (es) 2009-05-21

Family

ID=38178635

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004890A MX2009004890A (es) 2006-11-09 2006-11-09 Direccionamiento de subunidades alpha-1 o alpha-3 de na+, k+-atpasa en el tratamiento de enfermedades proliferativas.

Country Status (8)

Country Link
US (1) US20100068198A1 (es)
EP (1) EP2087112A1 (es)
JP (1) JP2010509251A (es)
CN (1) CN101583714A (es)
AU (1) AU2006350507A1 (es)
CA (1) CA2668346A1 (es)
MX (1) MX2009004890A (es)
WO (1) WO2008055530A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1397569B1 (it) 2009-12-10 2013-01-16 Icgeb Peptidi e loro derivati che inibiscono il rilascio extracellulare della proteina tat di hiv-1 e la replicazione di hiv-1.
US9095606B1 (en) 2010-11-13 2015-08-04 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US8734859B1 (en) 2010-11-13 2014-05-27 Sirbal Ltd. Molecular combinations for cancer or other disease treatment
US8541382B2 (en) 2010-11-13 2013-09-24 Sirbal Ltd. Cardiac glycoside analogs in combination with emodin for cancer therapy
US9066974B1 (en) 2010-11-13 2015-06-30 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US20170049687A1 (en) 2015-07-29 2017-02-23 Sirbal Ltd. Herbal Combinations For Treating Scalp Conditions
EP3498288A1 (en) 2013-12-02 2019-06-19 Sirbal Ltd. Herbal combinations for treatment of a skin condition
KR101701597B1 (ko) * 2014-03-20 2017-02-01 숙명여자대학교산학협력단 강심 배당체를 이용한 stk11-돌연변이 암 치료용 약학적 조성물
WO2015142117A1 (ko) * 2014-03-20 2015-09-24 숙명여자대학교산학협력단 강심 배당체를 이용한 stk11-돌연변이 암 치료용 약학적 조성물
EP2952898B1 (en) * 2014-06-06 2018-08-08 Euroimmun Medizinische Labordiagnostika AG Diagnosis of a neurological disease
ES2903397T3 (es) 2015-12-30 2022-04-01 Marshall Univ Research Corporation Composiciones y métodos para tratar la retinopatía
EP3897657A2 (en) * 2018-12-20 2021-10-27 Universität Basel <sup2/>? <sub2/>?+? ?na/k <ns1:sup>+</ns1:sup>?atpase inhibitors for use in the prevention or treatment of metastasis
CN112858679B (zh) * 2021-01-13 2024-06-18 中国水产科学研究院东海水产研究所 一种用于青海湖裸鲤肠道单细胞水平nka蛋白染色的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2461372C (en) * 2001-09-27 2014-01-07 Bionomics Limited Dna sequences for human angiogenesis genes
CA2480665A1 (en) * 2002-04-08 2003-10-23 The Regents Of The University Of California Use of na,k-atpase a-and b-subunits in bladder cancer detection and drug screening
AU2003237686A1 (en) * 2002-05-24 2003-12-12 Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. Rna interference mediating small rna molecules
US20070224201A1 (en) * 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ATE327240T1 (de) * 2002-10-09 2006-06-15 Unibioscreen Sa 2ß OXO-VORUSCHARIN UND DERIVATEN
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
WO2005004794A2 (en) * 2003-06-09 2005-01-20 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
CN102895673A (zh) * 2004-08-23 2013-01-30 西伦蒂斯私人股份公司 眼病的治疗
US20060135468A1 (en) * 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using NA+/K+ ATPase inhibitors
EP1859274A2 (en) * 2005-03-07 2007-11-28 Novartis AG Genes involved in neurodegenerative conditions
EP1977246B1 (en) * 2005-12-30 2010-01-20 Ventana Medical Systems, Inc. Na+, k+-atpase expression in cervical dysplasia and cancer

Also Published As

Publication number Publication date
CA2668346A1 (en) 2008-05-15
WO2008055530A1 (en) 2008-05-15
US20100068198A1 (en) 2010-03-18
AU2006350507A1 (en) 2008-05-15
EP2087112A1 (en) 2009-08-12
CN101583714A (zh) 2009-11-18
JP2010509251A (ja) 2010-03-25

Similar Documents

Publication Publication Date Title
SG164368A1 (en) Treatment of cancer
WO2008030883A3 (en) Treatment of cancer
MX2011010673A (es) Formulaciones de nanoparticulas y usos de las mismas.
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
PH12013500299B1 (en) Pyrrolopyrimidine compounds and uses thereof
EP3858347A3 (en) Psma binding ligand-linker conjugates and methods for using
IL184617A0 (en) Dr5 antibodies and uses thereof
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2009006577A3 (en) Compositions and methods for inhibiting ezh2
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
MX2010002179A (es) Composicion para el tratamiento de enfermedades neoplasicas.
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
MX2022009759A (es) El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4-ciano-3-trifl uorometil-fenil)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ili deno]-tiourea.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
JO3635B1 (ar) مركبات صيدلانية صلبة وطرق لانتاجها
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2008144507A3 (en) Spirooxindole inhibitors of aurora kinase
WO2007117161A1 (en) Substituted ring fused azines and their use in cancer therapy
MX2009004890A (es) Direccionamiento de subunidades alpha-1 o alpha-3 de na+, k+-atpasa en el tratamiento de enfermedades proliferativas.
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
WO2011056566A3 (en) Compounds and methods for treatment of cancer

Legal Events

Date Code Title Description
HH Correction or change in general